ARID1A mutation
|
NSCLC
|
ARID1A mutation
|
NSCLC
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
ARID1A mutation
|
NSCLC
|
ARID1A mutation
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
ARID1A mutation
|
RCC
|
ARID1A mutation
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
ARID1A mutation
|
HCC
|
ARID1A mutation
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Cholangiocarcinoma
|
ARID1A mutation
|
Cholangiocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Gastric Cancer
|
ARID1A mutation
|
Gastric Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Gastrointestinal Cancer
|
ARID1A mutation
|
Gastrointestinal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Head and Neck Cancer
|
ARID1A mutation
|
Head and Neck Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Breast Cancer
|
ARID1A mutation
|
Breast Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Bladder Cancer
|
ARID1A mutation
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Endometrial Cancer
|
ARID1A mutation
|
Endometrial Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Pancreatic Ductal Adenocarcinoma
|
ARID1A mutation
|
Pancreatic Ductal Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Melanoma
|
ARID1A mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Neuroendocrine Tumor
|
ARID1A mutation
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Solid Tumor
|
ARID1A mutation
|
Solid Tumor
|
AZD6738 Sensitive: C3 – Early Trials
|
AZD6738 Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Cervical Cancer
|
ARID1A mutation
|
Cervical Cancer
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Endometrial Cancer
|
ARID1A mutation
|
Endometrial Cancer
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Cholangiocarcinoma
|
ARID1A mutation
|
Cholangiocarcinoma
|
sintilimab Sensitive: C4 – Case Studies
|
sintilimab Sensitive: C4 – Case Studies
|
ARID1A mutation
|
CRC
|
ARID1A mutation
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
ARID1A mutation
|
Ovarian Cancer
|
ARID1A mutation
|
Ovarian Cancer
|
GSK2816126 Sensitive: D – Preclinical
|
GSK2816126 Sensitive: D – Preclinical
|
ARID1A mutation
|
Bladder Cancer
|
ARID1A mutation
|
Bladder Cancer
|
GSK2816126 Sensitive: D – Preclinical
|
GSK2816126 Sensitive: D – Preclinical
|
ARID1A mutation
|
Gastric Cancer
|
ARID1A mutation
|
Gastric Cancer
|
EZH2 inhibitor Sensitive: D – Preclinical
|
EZH2 inhibitor Sensitive: D – Preclinical
|
ARID1A mutation
|
Ovarian Cancer
|
ARID1A mutation
|
Ovarian Cancer
|
NXP900 Sensitive: D – Preclinical
|
NXP900 Sensitive: D – Preclinical
|
ARID1A mutation
|
Bladder Cancer
|
ARID1A mutation
|
Bladder Cancer
|
OTX015 Sensitive: D – Preclinical
|
OTX015 Sensitive: D – Preclinical
|